CR20230132A - Inhibidores de apol1 y métodos para usar los mismos - Google Patents

Inhibidores de apol1 y métodos para usar los mismos

Info

Publication number
CR20230132A
CR20230132A CR20230132A CR20230132A CR20230132A CR 20230132 A CR20230132 A CR 20230132A CR 20230132 A CR20230132 A CR 20230132A CR 20230132 A CR20230132 A CR 20230132A CR 20230132 A CR20230132 A CR 20230132A
Authority
CR
Costa Rica
Prior art keywords
apol1
methods
inhibitors
tautomer
strong
Prior art date
Application number
CR20230132A
Other languages
English (en)
Inventor
Jun Myun Ahn
Jingrong Cao
John E Cochran
Akira Joseph Shimizu
Timothy J Senter
Suganthini S Nanthakumar
Dowd Hardwin O
Haoxuan Wang
Jon H Come
Michael Aaron Brodney
Samantha Angle
Elena Dolgikh
Steven David Stone
Brad D Maxwell
Jessica Howard Olsen
Leslie A Dakin
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of CR20230132A publication Critical patent/CR20230132A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona al menos una entidad elegida de los Compuestos de la Fórmula <strong>I, </strong>un tautómero del mismo, un derivado deuterado de ese compuesto o tautómero, y una sal farmacéuticamente aceptable de cualquiera de los anteriores, composiciones que comprenden los mismos, y métodos para usar los mismos, incluyendo los usos en el tratamiento de enfermedades mediadas por APOL1, incluyendo cáncer pancreático, glomeruloesclerosis segmentaria focal (FSGS), y/o enfermedad renal no diabética (NDKD). Fórmula <strong>I</strong>
CR20230132A 2020-08-26 2021-08-26 Inhibidores de apol1 y métodos para usar los mismos CR20230132A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063070705P 2020-08-26 2020-08-26
PCT/US2021/047754 WO2022047031A1 (en) 2020-08-26 2021-08-26 Inhibitors of apol1 and methods of using same

Publications (1)

Publication Number Publication Date
CR20230132A true CR20230132A (es) 2023-06-27

Family

ID=77822053

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230132A CR20230132A (es) 2020-08-26 2021-08-26 Inhibidores de apol1 y métodos para usar los mismos

Country Status (20)

Country Link
US (1) US11866446B2 (es)
EP (1) EP4204423A1 (es)
JP (1) JP2023539194A (es)
KR (1) KR20230057386A (es)
CN (1) CN116547287A (es)
AR (1) AR123355A1 (es)
AU (1) AU2021333776A1 (es)
BR (1) BR112023003423A2 (es)
CA (1) CA3190609A1 (es)
CL (1) CL2023000536A1 (es)
CO (1) CO2023003026A2 (es)
CR (1) CR20230132A (es)
DO (1) DOP2023000042A (es)
EC (1) ECSP23020167A (es)
IL (1) IL300298A (es)
MX (1) MX2023002269A (es)
PE (1) PE20231106A1 (es)
TW (1) TW202227456A (es)
UY (1) UY39395A (es)
WO (1) WO2022047031A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202105769XA (en) 2018-12-17 2021-07-29 Vertex Pharma Inhibitors of apol1 and methods of using same
MX2022010748A (es) 2020-03-06 2022-09-23 Vertex Pharma Metodos para tratar la glomeruloesclerosis segmentaria focal dependiente de apolipoproteina l1 (apol-1).
US11866446B2 (en) 2020-08-26 2024-01-09 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
KR20240051990A (ko) * 2021-08-26 2024-04-22 버텍스 파마슈티칼스 인코포레이티드 스피로트리시클릭 apol1 억제제의 고형분 형태 및 이의 사용 방법
US11976067B2 (en) 2022-01-18 2024-05-07 Maze Therapeutics, Inc. APOL1 inhibitors and methods of use
WO2023154344A1 (en) * 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated 2-methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039676A (en) 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
CA2262569A1 (en) 1996-08-09 1998-02-19 Norihito Ohi Benzopiperidine derivatives
AU7514700A (en) 1999-09-07 2001-04-10 Syngenta Participations Ag Cyanopiperidines
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
WO2002028831A1 (en) 2000-10-02 2002-04-11 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
WO2003104180A1 (en) 2002-06-05 2003-12-18 Natco Pharma Limited Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
US7728150B2 (en) 2004-03-03 2010-06-01 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
JP5406722B2 (ja) 2006-10-16 2014-02-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ブラジキニン１受容体モジュレータとしての置換されたスルホンアミド誘導体
US8084609B2 (en) 2006-12-22 2011-12-27 Hoffman-La Roche Inc. Spiropiperidine derivatives
DK2118074T3 (en) 2007-02-01 2014-03-10 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
JP5323834B2 (ja) 2007-08-17 2013-10-23 エルジー・ライフ・サイエンシーズ・リミテッド 細胞壊死阻害剤としてのインドール化合物
US9101616B2 (en) 2009-05-29 2015-08-11 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
WO2011060217A1 (en) 2009-11-16 2011-05-19 Eli Lilly And Company Spiropiperidine compounds as orl-1 receptor antagonists
UA107943C2 (en) 2009-11-16 2015-03-10 Lilly Co Eli Compounds of spiropiperidines as antagonists of the orl-1 receptors
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
BR102012024778A2 (pt) 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
WO2014085154A1 (en) 2012-11-27 2014-06-05 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
WO2015048301A1 (en) 2013-09-26 2015-04-02 Pharmakea, Inc. Autotaxin inhibitor compounds
WO2016029310A1 (en) 2014-08-27 2016-03-03 The Governing Council Of The University Of Toronto Cannabinoid type 1 receptor modulators
WO2016055517A1 (en) 2014-10-08 2016-04-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel aminopyridine compounds useful as inhibitors of protein prenylation
TW201632522A (zh) 2014-11-21 2016-09-16 伊史帝夫博士實驗室股份有限公司 針對疼痛具有多模式活性的螺－異喹啉－１，４’－哌啶化合物
EP3858825A1 (en) 2015-08-27 2021-08-04 Pfizer Inc. Bicyclic-fused heteroaryl compounds as irak4 modulators
JP6990657B2 (ja) 2016-02-08 2022-01-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｄｄｒ１阻害剤としてのスピロインドリノン
US11267780B2 (en) 2018-04-30 2022-03-08 The Trustees Of Indiana University Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease
SG11202105769XA (en) 2018-12-17 2021-07-29 Vertex Pharma Inhibitors of apol1 and methods of using same
US20220144838A1 (en) 2019-03-13 2022-05-12 Nanjing Immunophage Biotech Co., Ltd. Compounds as Inhibitors of Macrophage Migration Inhibitory Factor
EP4076423A4 (en) 2019-12-19 2024-03-13 Casma Therapeutics Inc TRPML MODULATORS
AU2021213758A1 (en) 2020-01-29 2022-09-01 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
WO2021158666A1 (en) 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
MX2022010748A (es) 2020-03-06 2022-09-23 Vertex Pharma Metodos para tratar la glomeruloesclerosis segmentaria focal dependiente de apolipoproteina l1 (apol-1).
EP4139291A4 (en) 2020-04-22 2024-05-29 Anima Biotech Inc COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications
EP4146633A1 (en) 2020-05-07 2023-03-15 Rambam Med-Tech Ltd. Composition for use in the treatment of apol1-associated disease
KR20230024330A (ko) 2020-06-12 2023-02-20 버텍스 파마슈티칼스 인코포레이티드 Apol1 억제제의 고형분 형태 및 이의 사용 방법
AU2021286666A1 (en) 2020-06-12 2023-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and use of the same
CA3185604A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
US11866446B2 (en) 2020-08-26 2024-01-09 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
KR20240051990A (ko) 2021-08-26 2024-04-22 버텍스 파마슈티칼스 인코포레이티드 스피로트리시클릭 apol1 억제제의 고형분 형태 및 이의 사용 방법

Also Published As

Publication number Publication date
ECSP23020167A (es) 2023-12-29
UY39395A (es) 2022-03-31
AR123355A1 (es) 2022-11-23
PE20231106A1 (es) 2023-07-19
US11866446B2 (en) 2024-01-09
MX2023002269A (es) 2023-05-16
JP2023539194A (ja) 2023-09-13
BR112023003423A2 (pt) 2023-03-21
DOP2023000042A (es) 2023-07-09
CO2023003026A2 (es) 2023-03-17
AU2021333776A1 (en) 2023-03-16
TW202227456A (zh) 2022-07-16
CA3190609A1 (en) 2022-03-03
US20220106327A1 (en) 2022-04-07
WO2022047031A1 (en) 2022-03-03
CN116547287A (zh) 2023-08-04
EP4204423A1 (en) 2023-07-05
IL300298A (en) 2023-04-01
CL2023000536A1 (es) 2023-09-08
KR20230057386A (ko) 2023-04-28

Similar Documents

Publication Publication Date Title
CR20230132A (es) Inhibidores de apol1 y métodos para usar los mismos
CR20190124A (es) Inhibidores de ssao de aminopirimidina
EA202092899A1 (ru) Гетероарильные соединения для лечения болезни гентингтона
JOP20210130A1 (ar) مثبطات apol1 وطرق استخدامها
EA201691142A1 (ru) Ингибиторы мек и способы их применения
BR112021002267A8 (pt) Inibidores de prmt5
EA202090052A1 (ru) Содержащие имидазол ингибиторы alk2 киназы
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
ECSP055745A (es) Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona
CL2022003360A1 (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados (divisional de la solicitud 202002578)
AR122351A1 (es) Derivados de metilquinazolinona como inhibidores de braf
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
CO2024001367A2 (es) Compuestos antivirales
CO2022014272A2 (es) Agente para el tratamiento de lesión renal aguda inducida por medio de contraste
CL2021003202A1 (es) Compuestos de pirrolidina
BR112022005706A2 (pt) Inibidores de 1,6-naftiridina substituída de cdk5
DK1301475T3 (da) Arylsulfonamider, som serotoninantagonist til behandling af obesitet
UY39799A (es) Compuestos de pirrolil–sulfonamida
CO2021017202A2 (es) Compuestos tricíclicos
EA202191741A1 (ru) Аналоги пентамидина и их применение
EA202190766A1 (ru) Иммуномодуляторы, их композиции и способы применения
AR125358A1 (es) Inhibidores heteroaromáticos bicíclicos de la peptidasa 5 relacionada con la calicreína (klk5)
EA202192859A1 (ru) ПРОИЗВОДНЫЕ ТЕТРАГИДРО-1Н-ЦИКЛОПЕНТА[cd]ИНДЕНА В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА-2 (АЛЬФА), ИНДУЦИРУЕМОГО ГИПОКСИЕЙ
AR119967A1 (es) Degradadores bifuncionales de brd9 y sus métodos de uso
EA202192382A1 (ru) Соединения, нацеленные на prmt5